IMR Press / CEOG / Volume 38 / Issue 2 / pii/1630488779396-2033012105

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Is there any effect of fetal gender on the markers of first trimester Down's Syndrome screening?
Show Less
1 Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Idi-Araba, Lagos (Nigeria)
Clin. Exp. Obstet. Gynecol. 2011, 38(2), 162–164;
Published: 10 June 2011
Abstract

Introduction: At present, the most effective trisomy 21-screening method is the estimate of risk combining maternal age, fetal nuchal translucency, beta-hCG and pregnancy-associated PAPP-A. Objective: The aim of this study was to investigate the possible effect of fetal gender in first trimester Down's syndrome screening markers. Design: Retrospective study. Setting: Prenatal Diagnosis Centre in a tertiary hospital in I agos. Methods: Of a total of 350 pregnancies in which fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A were performed were included in this study. These markers were investigated to see if they differed on the basis of fetal gender. Results: PAPP-A levels were higher in female fetuses although the difference was not statistically significant. Nuchal translucency was 0.099 mm more in male fetuses. Conclusion: The results suggest that first trimester markers differ on gender but are of no clinical significance, confirming the result of other authors.
Keywords
Gender
Down's syndrome
Screening
Biochemical
Nuchal translucency
Share
Back to top